Healthcare Industry News: Ranbaxy Laboratories
News Release - April 11, 2007
Ranbaxy Receives Approval To Market Cefprozil Tablets and Cefprozil Powder For Oral Suspension in Canada
TORONTO, April 11 (Healthcare Sales & Marketing Network) -- Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that Ranbaxy has received approval to manufacture and market RAN(TM)-Cefprozil Tablets, 250mg and 500mg, and RAN(TM)-Cefprozil Powder for Oral Suspension, 250mg/5mL from Health Canada. The total market size for Cefzil(TM)(x) in Canada was CAD 28.2 million dollars (IMS-MAT: Dec 2006).Cefprozil Tablets and Powder for Oral Suspension are indicated for the treatment of upper respiratory tract infections, uncomplicated skin and urinary tract infections.
"We are pleased to receive these approvals for RAN(TM)-Cefprozil, Tablets and Powder for Oral Suspension to expand the number of product offerings that Ranbaxy commercializes for use by patients who require the therapeutic benefits of this product where indicated. This further adds to our expanding generic product portfolio which will have benefits of offering an affordable generic alternative to the brand that will now be accessible to all Canadians," according to Bill Abboud, President, RPCI.
Ranbaxy Pharmaceuticals Canada Inc., (RPCI) based in Mississauga, Ontario, Canada, is a wholly subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.
Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 9 countries.
(x)Cefzil(TM), Bristol-Myers Squibb Canada Inc., Canada
Source: Ranbaxy Laboratories
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
